Aclaris 8-K Formalizes Positive ATI-052 Phase 1b Data; Cash of ~$204.6M at Sept 30
ACRS sits 92% above its 52-week low of $2.095.
Summary
Aclaris filed an 8-K furnishing the Phase 1b ATI-052 results already released this morning and disclosed preliminary cash of about $204.6 million as of September 30, 2026, enough to support the planned Phase 2b EoE trial in early 2027.
Key Events · Product Development and Regulatory · ACRS
-
Positive ATI-052 Phase 1b Results Furnished
In severe atopic dermatitis, ATI-052 showed a 45% placebo-adjusted mean EASI improvement at day 57 (58% active vs 13% placebo) and 78% placebo-adjusted EASI-50; in asthma, a single 480 mg dose cut FeNO 59% (45 ppb) at day 15 versus 15% on placebo.
-
Preliminary Cash of ~$204.6M at Sept 30
Company estimates cash, cash equivalents and marketable securities of approximately $204.6 million as of September 30, 2026 — unaudited, not reviewed by its auditors, and subject to material change.
-
Safety Profile Clean Across Both Trials
No Grade 3 or Grade 4 treatment-emergent adverse events, no discontinuations due to adverse events, and no conjunctivitis observed in the Phase 1a/1b ATI-052 program.
-
EoE Prioritized; Phase 2b Early 2027
Aclaris intends to prioritize ATI-052 development initially in eosinophilic esophagitis and expects to initiate a Phase 2b trial in early 2027, with an update on an additional indication in the near term.
Analysis · ACRS · Life Sciences
The clinical substance was already public this morning via the press release, so the incremental news here is the formal 8-K package plus a preliminary cash balance of roughly $204.6 million at September 30, 2026 — unaudited and subject to change. Against a company that has been funding itself through an at-the-market program, that cash position suggests the Phase 2b plan in eosinophilic esophagitis (targeted for early 2027) looks financeable without an immediate raise. The data themselves are the story: a 45% placebo-adjusted EASI improvement at day 57 in severe atopic dermatitis and a 59% mean FeNO reduction 15 days after a single asthma dose, with no Grade 3/4 adverse events and no conjunctivitis. Caveats matter — the per-protocol AD analysis rests on nine active and one placebo patient, and the company itself notes cross-trial comparisons to dupilumab are not valid.
How filings like this one have moved
In the 30 days to Oct 28, 2026, 36.5% of the 953 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.66%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ACRS was trading at $4.03 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $557.9M. The 52-week trading range was $2.10 to $6.60. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.